Topic: Failed drug program
Inhaled sodium nitrite missed both primary and secondary objectives in heart failure patients with preserved ejection fraction.
The decision follows data from two phase 2 trials that tested angiopoietin 2 antibody nesvacumab in combination with Eylea.
Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.
Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.
Prothena has decided to abandon a T helper cell-targeting drug after it failed to hit the mark in a phase 1b study in psoriasis.
Versartis’ somavaratan has failed to match Pfizer’s Genotropin in phase 3, wiping more than 80% off its stock price.
The ear disease firm is laying off one-third of its noncommercial staff and hitting pause on its remaining pipeline programs.
A GNE myopathy trial missed its primary endpoint and all key secondary endpoints, delivering a blow to Ultragenyx as it enters a critical period.
Inotek Pharmaceuticals has posted its second set of subpar data of 2017.
Acceleron Pharma has jettisoned dalantercept after the inhibitor of ALK1 signaling failed to move the needle in a phase 2 kidney cancer trial.